FLR is not a strong buy right now for a beginner long-term investor with $50,000-$100,000, despite the positive pre-market move and improving analyst sentiment. The stock is trading above key short-term levels and has multiple supportive catalysts, but the latest quarterly financials were weak, insider selling is elevated, and there is no proprietary AI Stock Picker or SwingMax buy signal today. My clear view: hold off on buying aggressively right now; the setup is constructive, but not compelling enough for an immediate long-term entry at this price.
FLR is showing a bullish near-term setup: pre-market price is 53.5, up 4.74%, and the stock is above the pivot at 51.31 and near resistance at 54.10. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which supports the trend. MACD histogram is positive at 0.247 but contracting, suggesting momentum is still positive but losing some strength. RSI_6 at 45.88 is neutral, so it is not overbought. Overall, the technical picture is mildly bullish, but the stock is close enough to resistance that upside may be limited in the very short term.

Fluor sold its NuScale stake for $2.43B, strengthening the balance sheet and supporting share repurchases. Citi, UBS, and Truist all raised price targets recently and kept Buy ratings. The company also won a feasibility study for Anglo American's Woodsmith mining project, which adds a fresh project catalyst. The market is also approaching the Q1 earnings release, and the stock is in pre-market strength.
Latest quarter financials were weak: revenue fell 1.97% YoY, net income declined sharply, EPS turned negative, and gross margin contracted significantly. Insider selling has increased dramatically over the last month, which is a negative sentiment signal. Baird remains Neutral and says earnings power is still muted. The stock is also facing an earnings event with expectations for lower EPS and revenue YoY, which limits confidence in an immediate long-term entry.
In the latest reported quarter, Q4 2025, Fluor showed deterioration in operating performance. Revenue was $4.176B, down 1.97% YoY. Net income was -$1.573B, a sharp decline of 184.43% YoY. EPS came in at -9.77, also down 191.74% YoY. Gross margin fell to 3.18%, down 34.84% YoY. For a long-term beginner investor, this is the biggest concern because the latest season points to weak profitability despite the balance-sheet improvement from the NuScale sale.
Recent analyst trend is positive overall. Citi raised its price target to $61 from $57 and kept a Buy rating. UBS raised its target to $57 from $52 and kept Buy, citing a second-half backlog inflection. Truist raised its target to $59 from $56 and kept Buy after the Q4 earnings beat, highlighting a fresh start in 2026 and accelerating bookings. Baird remains more cautious, raising its target to $48 from $45 but keeping Neutral, saying earnings power is still muted. Wall Street is leaning bullish, but there is still a clear skeptical camp.